Plus Therapeutics announced it will change its name to Cerenome and trade under the new Nasdaq ticker CNSY starting August 3, 2026. The company affirmed its 2026 guidance, focusing on advancing its CNS cancer therapeutic REYOBIQ and expanding its CNSide Diagnostics platform, which has significantly grown payer coverage and physician adoption. Key milestones include progressing clinical trials for REYOBIQ, scaling commercial manufacturing, and expanding CNSide's diagnostic tests and Medicare reimbursement. The rebranding reflects the company's integrated approach combining therapeutics, diagnostics, and AI to improve CNS cancer patient outcomes.
During the first LEPAS Global Elegant Lifestyle Week, 34 ambassadors from 15 countries tested the LEPAS L6 EV on a 700 km route from Shanghai to Wuhu. The vehicle showcased strong performance across city, highway, and mountain roads, praised for its ...
During the first LEPAS Global Elegant Lifestyle Week, 34 Elegant Driving Ambassadors from 15 countries participated in the inaugural LEPAS Global Journey of Elegant Driving, driving the LEPAS L6 EV nearly 700 kilometers from Shanghai to Wuhu. The jou...
During the first LEPAS Global Elegant Lifestyle Week, 34 drivers from 15 countries tested the LEPAS L6 EV on a nearly 700 km journey across varied terrains in China. The vehicle's smooth power delivery, advanced electric drivetrain, and smart feature...
During the inaugural LEPAS Global Elegant Lifestyle Week, 34 ambassadors from 15 countries tested the LEPAS L6 EV on a 700km route in China, experiencing its versatile performance on urban roads, highways, and mountain paths. The vehicle's advanced c...
During the first LEPAS Global Elegant Lifestyle Week, 34 ambassadors from 15 countries tested the LEPAS L6 EV on a nearly 700 km route across China, highlighting its smooth power delivery, refined handling, and advanced smart features. The vehicle's ...
